The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
cAMP signalling in insulin and glucagon secretion
Abstract
The “second messenger” archetype cAMP is one of the most important cellular signalling molecules with central functions including the regulation of insulin and glucagon secretion from the pancreatic β‐ and α‐cells, respectively. cAMP is generally considered as an amplifier of insulin secretion triggered by Ca 2+ elevation in the β‐cells. Both messengers are also positive modulators of glucagon release from α‐cells, but in this case cAMP may be the important regulator and Ca 2+ have a more permissive role. The actions of cAMP are mediated by protein kinase A (PKA) and the guanine nucleotide exchange factor Epac. The present review focuses on how cAMP is regulated by nutrients, hormones and neural factors in β‐ and α‐cells via adenylyl cyclase‐catalysed generation and phosphodiesterase‐mediated degradation. We will also discuss how PKA and Epac affect ion fluxes and the secretory machinery to transduce the stimulatory effects on insulin and glucagon secretion. Finally, we will briefly describe disturbances of the cAMP system associated with diabetes and how cAMP signalling can be targeted to normalize hypo‐ and hypersecretion of insulin and glucagon, respectively, in diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 2×
“Closure of KATP channels may also be facilitated by Epac2,(95) which binds to the SUR1 subunit of the channel.(81) The”
BackgroundRenström, E., Eliasson, L., & Rorsman, P. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.105bl.x · Cited by 299 · cited 2×
“This conclusion is consistent with results from capacitance measurements of exocystosis.(80,89) The combination of PKA and Epac activators is more efficient than either activator alone.”
BackgroundResultIncreased melatonin signaling is a risk factor for type 2 diabetes
Tuomi, T., Nagorny, C. L. F., Singh, P., Bennet, H., Yu, Q., Alenkvist, I., Isomaa, B., Östman, B., Söderström, J., Pesonen, A.-K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.009 · Cited by 262
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 4×
“inhibition and stimulation of glucagon secretion could be mimicked by low and high concentrations of AC-activating forskolin.(112) However, direct recordings of cAMP indicated that individual α-cells located within islets only rarely respond to GLP-1.”
BackgroundInfluentialSUR1 Regulates PKA-independent cAMP-induced Granule Priming in Mouse Pancreatic B-cells
Eliasson, L., Ma, X., Renström, E., Barg, S., Berggren, P.-O., Galvanovskis, J., Gromada, J., Jing, X., Lundquist, I., Salehi, A., et al. (2003) · The Journal of General Physiology · doi:10.1085/jgp.20028707 · Cited by 257
Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Adriaenssens, A. E., Svendsen, B., Lam, B. Y. H., Yeo, G. S. H., Holst, J. J., Reimann, F., & Gribble, F. M. (2016) · Diabetologia · doi:10.1007/s00125-016-4033-1 · Cited by 223
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“180,181,183 187 Interactions with other pathways GLP-1 not only promotes the release of insulin but also enhances the response of pancreatic β -cells to insulin through the PI3K/Akt pathway, thereby improving insulin signal transduction and increasing the sensitivity of peripheral tissues to…”
BackgroundRamracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes
Omar-Hmeadi, M., Lund, P.-E., Gandasi, N. R., Tengholm, A., & Barg, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15717-8 · Cited by 105
Self-citationNew progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Gonçalves, D. A., Silveira, W. A., Manfredi, L. H., Graça, F. A., Armani, A., Bertaggia, E., O´Neill, B. T., Lautherbach, N., Machado, J., Nogara, L., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12395 · Cited by 56
Metadata
- Authors
- Tengholm, A., & Gylfe, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-09
- Volume
- 19
- Issue
- S1
- Pages
- 42-53
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2610797963
- Cited by
- 220
- References
- 24
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: cAMP signalling in insulin and glucagon secretion. https://app.cochat.ai/papers/10.1111/dom.12993
- The paper
- Tengholm, A., & Gylfe, E. (2017). cAMP signalling in insulin and glucagon secretion. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12993
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.